RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $42
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Kennen MacKay maintains an Outperform rating on Agios Pharmaceuticals (NASDAQ:AGIO) and raises the price target from $40 to $42.
June 27, 2023 | 11:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Agios Pharmaceuticals and raises the price target from $40 to $42.
RBC Capital's decision to maintain an Outperform rating and raise the price target for Agios Pharmaceuticals indicates a positive outlook for the company's stock. This news is likely to have a positive impact on AGIO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100